Skip to main content
SpringerLink
Log in

Progestin-Regulated Genes and Breast Cancer Risk: Good or Bad?

  • Chapter
Hormonal Carcinogenesis IV

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Graham JD, Clarke CL (1997) Physiological action of progesterone in target tissues. Endocr Rev 18:502–519.

    Article  PubMed  CAS  Google Scholar 

  2. King RJB (1993) Estrogen and progestin effects in human breast carcinogenesis. Breast Cancer Res Treat 27:3–15

    Article  PubMed  CAS  Google Scholar 

  3. Plu-Bureau G, Lê MG, Sitruk-Ware R, et al (1994) Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease. Br J Cancer 70:270–277.

    PubMed  CAS  Google Scholar 

  4. Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288:321–333.

    Article  Google Scholar 

  5. Magnusson C, Baron JA, Correja N, et al (1999) Breast cancer risk following long-term oestrogen-and oestrogen-progestin-replacement therapy. Int J Cancer 81:339–344.

    Article  PubMed  CAS  Google Scholar 

  6. Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92:328–32.

    Article  PubMed  CAS  Google Scholar 

  7. Schairer C, Lubin J, Troisi R, et al (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283:485–491.

    Article  PubMed  CAS  Google Scholar 

  8. Vignon F, Bardon S, Chalbos D, et al (1983) Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture. J Clin Endocrinol Metab 56:1124–1130.

    PubMed  CAS  Google Scholar 

  9. Gompel A, Malet C, Sprotzer P, et al (1986) Progestin effect on cell proliferation and 17 beta-hydroxysteroid dehydrogenase activity in normal human breast cells in culture. J Clin Endocrinol Metab 63:1174–1180.

    PubMed  CAS  Google Scholar 

  10. Sitruk-Ware R (2000) Progestins in hormonal replacement therapy and prevention of endometrial disease in clinical practice. In: Sitruk-Ware R, Mishell Jr DR (eds) Progestins and Antiprogestins. New York: Marcel Dekker, Inc., 269–278

    Google Scholar 

  11. Haslam SZ (1988) Progesterone effects on deoxyribonucleic acid synthesis in normal mouse mammary glands. Endocrinology 122:464–470.

    PubMed  CAS  Google Scholar 

  12. Raafat AM, Li S, Bennett JM, et al (2001) Estrogen and estrogen plus progestin act directly on the mammary gland to increase proliferation in a postmenopausal mouse model. Cell Physiol 187:81–89.

    Article  CAS  Google Scholar 

  13. Lydon JP, Ge G, Kittrell FS, et al (1999) Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function. Cancer Res 59:4276–84.

    PubMed  CAS  Google Scholar 

  14. Conneely OM, Mulac-Jercevic B, Lydon JP, De Mayo F (2002) Distinct and overlapping reproductive activities of the PR-A and PR-B isoforms of the progesterone receptor. Abstract S28-4, Int Congress Hormones and Cancer, Fukuoka, Oct 2002.

    Google Scholar 

  15. De Vivo I, Huggins GS, Hankinson SE, et al (1999) A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc. Nat. Acad. Sci. USA 99:12263–12268.

    Article  CAS  Google Scholar 

  16. Rochefort H, Chalbos D (1984) Progestin specific markers in human cell lines: biological and pharmacological applications. Mol Cell Endocrinol 36:3–10.

    Article  PubMed  CAS  Google Scholar 

  17. Chalbos D, Rochefort H (1984) Dual effects of the progestin R5020 on proteins released by the T47D human breast cancer cells. J Biol Chem 259:1231–1238

    PubMed  CAS  Google Scholar 

  18. Chalbos D, Westley B, May F, et al (1986) Cloning of cDNA sequences of a progestin-regulated mRNA from MCF7 human breast cancer cells. Nucleic Acids Res 14:965–982.

    PubMed  CAS  Google Scholar 

  19. Chalbos D, Haagensen D, Parish T, et al (1987) Identification and androgen regulation of two proteins released by the T47D human breast cancer cells. Cancer Res 47:2782–2792.

    Google Scholar 

  20. Pasqualini JR, Chetrite G, Blacker C, et al (1996) Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre-and postmenopausal breast cancer patients. J Clin Endocrinol Metab 81:1460–1464.

    Article  PubMed  CAS  Google Scholar 

  21. Chalbos D, Galtier F (1994) Differential effect of forms A and B of human progesterone receptor on estradiol-dependent transcription. J Biol Chem 269:23007–23012.

    PubMed  CAS  Google Scholar 

  22. Maudelonde T, Lavaud P, Salazar G, et al (1991) Progestin treatment depresses estrogen receptor but not cathepsin D levels in needle aspirates of benign breast disease. Breast Cancer Res Treat 19:95–102.

    Article  PubMed  CAS  Google Scholar 

  23. McGuire WL, Clark GM (1992) Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 326:1756–1761.

    Article  PubMed  CAS  Google Scholar 

  24. Hayashido Y, Lucas A, Rougeot C, et al (1998) Estradiol and Fibulin-1 inhibit motility of human ovarian and breast cancer cells induced by fibronectin. Int J Cancer 75:654–658.

    Article  PubMed  CAS  Google Scholar 

  25. Rochefort H, Platet N, Hayashido Y, et al (1998) Estrogen receptor mediated inhibition of cancer cell invasion and motility: an overview. J Steroid Biochem Molec Biol 65:163–168

    Article  PubMed  CAS  Google Scholar 

  26. Gompel A, Somai S, Chaouat M, et al (2000) Hormonal regulation of apoptosis in breast cells and tissues. Steroids 65:593–598.

    Article  PubMed  CAS  Google Scholar 

  27. Hyder SM, Chiappetta C, Stancel GM (2001) Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells. Int J Cancer 92:469–473.

    Article  PubMed  CAS  Google Scholar 

  28. Chalbos D and Rochefort H (1984) A 250-kilodalton cellular protein is induced by progestins in two human breast cancer cell lines MCF7 and T47D. Biochem Biophys Res Commun 121:421–427.

    Article  PubMed  CAS  Google Scholar 

  29. Chalbos D, Chambon M, Ailhaud G, et al (1987) Fatty acid synthetase and its mRNA are induced by progestins in breast cancer cells. J Biol Chem 262:9923–26.

    PubMed  CAS  Google Scholar 

  30. Wakil S (1989) Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 28:4523–4530.

    Article  PubMed  CAS  Google Scholar 

  31. Chalbos D, Galtier F, Emiliani S, et al (1991) The antiprogestin RU486 stabilizes the progestin-induced FAS mRNA but does not stimulate its transcription. J Biol Chem 266:8220–8224.

    PubMed  CAS  Google Scholar 

  32. Yang YA, Morin PJ, Han WF, et al (2002) Regulation of fatty acid synthase expression in breasr cancer by sterol regulatory element binding protein-1c. Exp Cell Res 282:132–137.

    Article  Google Scholar 

  33. Kumar-Sinha C, Ignatoski KW, Lippman ME, et al (2003) transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 63:132–139.

    PubMed  CAS  Google Scholar 

  34. Swinnen JV, Esquenet M, Goossens K, et al (1997) Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Cancer Res 57:1086–1090.

    PubMed  CAS  Google Scholar 

  35. Van de Sande T, De Schrijver E, Heyns W, et al (2002) Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res 62:642–646.

    PubMed  Google Scholar 

  36. Chalbos D, Escot C, Joyeux C, et al (1990) Expression of the progestin-induce fatty acid synthetase in benign mastopathies and breast cancer as measured by RNA in situ hybridisation. J.Natl Cancer Inst 82:602–606.

    PubMed  CAS  Google Scholar 

  37. Joyeux C, Chalbos D, Rochefort H (1990) Effects of progestins and menstrual cycle on fatty acid synthetase and progesterone receptor in human mammary glands. J Clin Endocrinol Metab 70:1438–1444.

    PubMed  CAS  Google Scholar 

  38. Chambon M, Rochefort H, Vial HJ, et al (1989) Progestins and androgens stimulate lipid accumulation in T47D breast cancer cells via their own receptors. J Steroid Biochem 33: 915–922.

    Article  PubMed  CAS  Google Scholar 

  39. Daling JR, Malone KE, Doody DR, et al (2002) Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 95:2455–2464.

    Article  PubMed  CAS  Google Scholar 

  40. Li CI, Stanford JL, Daling JR (2000) Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-ages women. Cancer 88:2570–2577.

    Article  PubMed  CAS  Google Scholar 

  41. Kuhajda FP, Piantadosi S, Pasternack GR (1989) Haptoglobin-related protein(Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N Engl J Med 321:636–641.

    Article  PubMed  CAS  Google Scholar 

  42. Alo PL, Visca P, Marci A, et al (1996) Expression of fatty acid syntase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77:474–82.

    Article  PubMed  CAS  Google Scholar 

  43. Kuhajda FP, Jenner K, Wood FD, et al (1994) Fatty acid synthase: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA 91:6379–6383.

    Article  PubMed  CAS  Google Scholar 

  44. Kuhadja FP, Pizer ES, Li JN, et al (2000) Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci USA 97: 3450–3454.

    Article  Google Scholar 

  45. Porter DA, Krop IE, Nasser S, et al (2001) A SAGE (Serial Analysis of Gene Expression) view of breast tumor progression. Cancer Res 61:5697–5702.

    PubMed  CAS  Google Scholar 

  46. Welsh JB, Sapinoso LM, Su AI, et al (2001) Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 61:5974–5978.

    PubMed  CAS  Google Scholar 

  47. Weiss L, Hoffmann GE, Schreiber R, et al (1986) Fatty-acid biosynthesis in man, a pathway of minor importance. Biol Chem Hoppe-Seyler 367:905–912.

    PubMed  CAS  Google Scholar 

  48. Chirala SS, Chang H, Matzuk M, et al (2003) Fatty acid synthesis is essential in embryonic development: fatty acid synthase null mutants and most of the heterozygotes die in utero. Proc Natl Acad Sci USA 100:6358–6363.

    Article  PubMed  CAS  Google Scholar 

  49. Pizer ES, Wood FD, Heine HS, et al (1996) Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res 56:1189–1193.

    PubMed  CAS  Google Scholar 

  50. Pizer ES, Jackisch C, Wood FD, et al (1996) Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res 56:2745–2747.

    PubMed  CAS  Google Scholar 

  51. Bardon S, Vignon F, Chalbos D, et al (1985) RU486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor. J Clin Endocrinol Metab 60:692–697.

    Article  PubMed  CAS  Google Scholar 

  52. Romieu G, Maudelonde T, Ulmann A, et al (1987) The antiprogestin RU486 in advanced breast cancer: Preliminary clinical trial. Bulletin du Cancer 74:455–461.

    PubMed  CAS  Google Scholar 

  53. Rochefort H, Glondu M, Esslimani Sahla M, et al (2003) How to target estrogen receptor negative breast cancer? Endocrine-Related Canc 10:1–6.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Inserm U.540 and Faculty of Medicine, Montpellier, France

    Henri Rochefort

Authors
  1. Henri Rochefort
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Majida Esslimani-Sahla
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dany Chalbos
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Etiology and Prevention of Hormonal Cancers, The University of Kansas Medical Center, 3901 Rainbow Boulevard, 2010 Breidenthal, Kansas City, KS, 66160-7417

    Jonathan J. Li (Profesor of Pharmacology, Toxicology and Therapeutics and Director) & Sara A. Li (Associate Research Professor of Pharmacology, Toxicology and Therapeutics) (Profesor of Pharmacology, Toxicology and Therapeutics and Director) &  (Associate Research Professor of Pharmacology, Toxicology and Therapeutics)

  2. Departmento de Patologia, Facultad de Medicina y Odontologia, Camino de Vera s/n, Valencia, 46071, Spain

    Antonio Llombart-Bosch (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Rochefort, H., Esslimani-Sahla, M., Chalbos, D. (2005). Progestin-Regulated Genes and Breast Cancer Risk: Good or Bad?. In: Li, J.J., Li, S.A., Llombart-Bosch, A. (eds) Hormonal Carcinogenesis IV. Springer, Boston, MA. https://doi.org/10.1007/0-387-23761-5_5

Download citation

  • DOI: https://doi.org/10.1007/0-387-23761-5_5

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-23783-1

  • Online ISBN: 978-0-387-23761-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation